Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment.

Nicolas-Boluda A, Vaquero J, Vimeux L, Guilbert T, Barrin S, Kantari-Mimoun C, Ponzo M, Renault G, Deptula P, Pogoda K, Bucki R, Cascone I, Courty J, Fouassier L, Gazeau F, Donnadieu E. · 2021

Read Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. by Nicolas-Boluda A, Vaquero J, Vimeux L, Guilbert T, Barrin S, Kantari-Mimoun C, Ponzo M, Renault G, Deptula P, Pogoda K, Bucki R, Cascone I, Courty J, Fouassier L, Gazeau F, Donnadieu E. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8203293.txt.

Description

Nicolas-Boluda and co-authors test whether softening a tumour helps T cells and immunotherapy. Dense matrix in tumours can wall T cells out. Only a share of patients gain from checkpoint inhibitors.

Across five mouse tumour models, stiffness rose with growth and matrix crosslinking. Stiffer tumours showed less T cell movement inside. Blocking lysyl oxidase cut collagen stabilisation and softened the tumours. T cell migration improved after that change. Anti-PD-1 treatment then worked better. The study ties a physical trait of tumours to a drug strategy. Matrix change, not just immune drugs, did part of the work.

Catalog record

CREATORNicolas-Boluda A, Vaquero J, Vimeux L, Guilbert T, Barrin S, Kantari-Mimoun C, Ponzo M, Renault G, Deptula P, Pogoda K, Bucki R, Cascone I, Courty J, Fouassier L, Gazeau F, Donnadieu E.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE94 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8203293

Browse the full library · About the Tower of Babel